• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Barinthus Biotherapeutics plc - American Depositary Shares (NQ: BRNS )

    0.8371 -0.1331 (-13.72%)
    Streaming Delayed Price Updated: 3:59 PM EST, Nov 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Barinthus Biotherapeutics plc - American Depositary Shares

    Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
    From Barinthus Biotherapeutics
    Via GlobeNewswire
    Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
    From Barinthus Biotherapeutics
    Via GlobeNewswire
    Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results
    From Barinthus Biotherapeutics
    Via GlobeNewswire
    Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences
    From Barinthus Biotherapeutics
    Via GlobeNewswire
    Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
    From Barinthus Biotherapeutics
    Via GlobeNewswire
    Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
    From Barinthus Biotherapeutics
    Via GlobeNewswire
    Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results
    From Barinthus Biotherapeutics
    Via GlobeNewswire
    Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
    From Barinthus Biotherapeutics
    Via GlobeNewswire
    Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
    From Barinthus Biotherapeutics
    Via GlobeNewswire
    Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024
    From Barinthus Biotherapeutics
    Via GlobeNewswire
    Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
    From Barinthus Biotherapeutics
    Via GlobeNewswire
    Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer
    Dr. Hooftman brings more than 25 years’ experience in international drug development including immunology, autoimmunity, hematology, oncology, and infectious diseases 
    From Barinthus Biotherapeutics
    Via GlobeNewswire
    Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
    From Barinthus Biotherapeutics
    Via GlobeNewswire
    Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments
    From Barinthus Biotherapeutics
    Via GlobeNewswire
    Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
    From Barinthus Biotherapeutics
    Via GlobeNewswire
    New partnership aims to advance vaccine against MERS coronavirus
    From Barinthus Biotherapeutics
    Via GlobeNewswire
    Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
    From Barinthus Biotherapeutics
    Via GlobeNewswire
    Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
    From Barinthus Biotherapeutics
    Via GlobeNewswire
    Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.